Insider Selling: Natera, Inc. (NASDAQ:NTRA) CEO Sells $233,201.76 in Stock

Natera, Inc. (NASDAQ:NTRA) CEO Steven Leonard Chapman sold 2,552 shares of Natera stock in a transaction dated Tuesday, April 23rd. The shares were sold at an average price of $91.38, for a total value of $233,201.76. Following the completion of the transaction, the chief executive officer now owns 230,319 shares in the company, valued at approximately $21,046,550.22. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Steven Leonard Chapman also recently made the following trade(s):

• On Monday, April 15th, Steven Leonard Chapman sold 6,816 shares of Natera stock. The shares were sold at an average price of $93.13, for a total value of $634,774.08.
• On Thursday, March 28th, Steven Leonard Chapman sold 2,662 shares of Natera stock. The shares were sold at an average price of $90.42, for a total value of $240,698.04.
• On Friday, March 15th, Steven Leonard Chapman sold 83,223 shares of Natera stock. The shares were sold at an average price of $88.96, for a total value of $7,403,518.08.
• On Tuesday, March 5th, Steven Leonard Chapman sold 9,326 shares of Natera stock. The shares were sold at an average price of $88.36, for a total value of $824,045.36.
• On Monday, January 29th, Steven Leonard Chapman sold 14,813 shares of Natera stock. The shares were sold at an average price of $65.09, for a total value of $964,178.17.

Natera Price Performance

Natera stock opened at $91.28 on Friday. The stock’s 50 day moving average is $87.29 and its 200 day moving average is $67.00. The company has a debt-to-equity ratio of 0.37, a current ratio of 4.10 and a quick ratio of 3.96. The firm has a market cap of $11.02 billion, a P/E ratio of -24.08 and a beta of 1.37. Natera, Inc. has a one year low of $36.90 and a one year high of $98.82.

Natera (NASDAQ:NTRA) last issued its quarterly earnings results on Wednesday, February 28th. The medical research company reported ($0.64) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.73) by $0.09. Natera had a negative return on equity of 62.19% and a negative net margin of 40.16%. The firm had revenue of $311.11 million for the quarter, compared to analyst estimates of $300.38 million. As a group, research analysts expect that Natera, Inc. will post -2.35 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on NTRA. BTIG Research lifted their target price on Natera from $75.00 to $85.00 and gave the company a “buy” rating in a research report on Friday, December 29th. The Goldman Sachs Group boosted their price target on Natera from $90.00 to $100.00 and gave the stock a “buy” rating in a report on Monday, April 15th. Craig Hallum began coverage on Natera in a report on Monday, April 8th. They set a “buy” rating and a $117.00 price target on the stock. Raymond James cut Natera from a “strong-buy” rating to an “outperform” rating and boosted their price target for the stock from $68.00 to $85.00 in a report on Tuesday, February 20th. Finally, Canaccord Genuity Group boosted their price target on Natera from $87.00 to $100.00 and gave the stock a “buy” rating in a report on Thursday, February 29th. One investment analyst has rated the stock with a sell rating and fourteen have assigned a buy rating to the company’s stock. According to data from MarketBeat, Natera currently has a consensus rating of “Moderate Buy” and an average price target of $86.40.

Hedge Funds Weigh In On Natera

Several institutional investors have recently added to or reduced their stakes in NTRA. National Bank of Canada FI acquired a new position in Natera in the third quarter valued at approximately $1,932,000. CWM LLC lifted its stake in Natera by 224.4% in the third quarter. CWM LLC now owns 1,317 shares of the medical research company’s stock valued at $58,000 after buying an additional 911 shares during the period. SG Americas Securities LLC lifted its stake in Natera by 1,503.2% in the third quarter. SG Americas Securities LLC now owns 97,973 shares of the medical research company’s stock valued at $4,335,000 after buying an additional 91,862 shares during the period. Ellsworth Advisors LLC acquired a new position in Natera in the third quarter valued at approximately $364,000. Finally, Xponance Inc. lifted its stake in Natera by 1.8% in the third quarter. Xponance Inc. now owns 14,506 shares of the medical research company’s stock valued at $642,000 after buying an additional 261 shares during the period. 99.90% of the stock is owned by institutional investors and hedge funds.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.